sap-001
Small moleculeexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 24, 2018 (NCT03857165)
Timeline
Indications
Studied for
Mechanism of action
- Solute carrier family 22 member 12INHIBITOR
SLC22A12 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06729853 | Phase 1/Phase 2 (Phase 2) | Apr 24, 2024 | Shanton Pharma Co., Ltd. |
| NCT06678581 | Phase 1 | May 29, 2023 | Shanton Pharma Co., Ltd. |
| NCT05690204 | Phase 2 | Dec 12, 2022 | Shanton Pharma Co., Ltd. |
| NCT04040816 | Phase 2 | Jan 1, 2019 | Shanton Pharma Co., Ltd. |
| NCT03857165 | Phase 1 | Sep 24, 2018 | Anaheim Clinical Trials, Avail Clinical Research, High Point Clinical Trial Center, Shanton Pharma Co., Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanton Pharma Co., Ltd. | For profit | 5 | 5 | 2 | 2018 |
| Anaheim Clinical Trials | For profit | 1 | 0 | 1 | 2018 |
| Avail Clinical Research | For profit | 1 | 0 | 1 | 2018 |
| High Point Clinical Trial Center | For profit | 1 | 0 | 1 | 2018 |
4 organizations
Page 1 / 1